Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Profession Retina, Retina, Glaucoma, Professional Development

This Month in Business

  • Novartis and Spark Therapeutics have entered a licensing agreement for Luxturna (voretigene neparvovec) in markets outside of the United States. Luxturna received FDA approval on December 19, 2017 for the treatment of patients with biallelic mutations in the RPE65 gene. A market authorization application was filed with the EMA on July 31, 2017, and, following approval, Novartis will obtain all commercialization rights. According to the press release, Novartis will make an upfront payment, as well as pay milestones and royalties to Spark Therapeutics reflective of the late stage of the opportunity.

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Ruth Steer

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register